Share on StockTwits

Genocea Biosciences (NASDAQ:GNCA) major shareholder Polaris Venture Management Co. sold 9,660 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $13.01, for a total transaction of $125,676.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Genocea Biosciences (NASDAQ:GNCA) traded up 2.08% during mid-day trading on Friday, hitting $13.23. The stock had a trading volume of 10,872 shares. Genocea Biosciences has a 52 week low of $10.90 and a 52 week high of $23.99. The stock has a 50-day moving average of $15.69 and a 200-day moving average of $17.07. The company’s market cap is $230.3 million.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Wednesday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. On average, analysts predict that Genocea Biosciences will post $-2.10 earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a United States-based clinical-stage company that develops T cell vaccines.

Receive News & Ratings for Genocea Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.